Thermoablation Friend and foe of immunotherapy

被引:0
|
作者
Radosa, Christoph G. [1 ]
Hoffmann, Ralf-Thorsten [1 ]
机构
[1] Tech Univ Dresden, Inst & Poliklin Diagnost & Intervent Radiol, Univ Klinikum Carl Gustav Carus, Fetscherstr 74, D-01307 Dresden, Germany
来源
RADIOLOGE | 2020年 / 60卷 / 08期
关键词
Combination therapy; Thermoablation; Immune system; Cancer immunity; Immunomodulation; RENAL-CELL CARCINOMA; HEAT-SHOCK PROTEINS; RADIOFREQUENCY ABLATION; THERMAL ABLATION; DENDRITIC CELLS; CANCER-IMMUNITY; TUMOR; MECHANISMS; EXPRESSION; GROWTH;
D O I
10.1007/s00117-020-00719-w
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background Evidence from multiple studies have shown the potential of thermal ablative therapies to induce regression of metastases and tumors which are distant from the treated metastases-within the same organ or even in other organs-the so-called abscopal effect. Unfortunately, this effect is most often weak and not always reproducible. Recent developments in systemic therapies showed that immunomodulating drugs are of major interest in patient-tailored tumor therapy due to the fact that they are able to enhance the treatment effect of conventional chemotherapy. Furthermore, several studies and reports showed that these immunomodulating therapies are also able to enhance the response of the immune system to the tumor-if combined with local ablative therapies-and trigger a systemic antitumor response. Unfortunately, there is also evidence that effects caused by thermal ablation can hamper the immune system and, therefore, increase tumor growth and tumor spread. Objectives In this article, the effects of thermal ablation in general are described, different (thermo-)ablative techniques are presented and a perspective of combination therapies is given.
引用
收藏
页码:704 / 710
页数:7
相关论文
共 50 条
  • [1] Ferroptosis: friend or foe in cancer immunotherapy?
    Demuynck, Robin
    Efimova, Iuliia
    Catanzaro, Elena
    Krysko, Dmitri, V
    [J]. ONCOIMMUNOLOGY, 2023, 12 (01):
  • [2] Friend or Foe: Hidden Dangers of Nivolumab Immunotherapy
    Morim, O.
    Koenig, S. J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [3] Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?
    Cong Yan
    Xiao-Xuan Tu
    Wei Wu
    Zhou Tong
    Lu-Lu Liu
    Yi Zheng
    Wei-Qin Jiang
    Peng Zhao
    Wei-Jia Fang
    Hang-Yu Zhang
    [J]. World Journal of Clinical Cases, 2019, (11) : 1253 - 1261
  • [4] Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?
    Yan, Cong
    Tu, Xiao-Xuan
    Wu, Wei
    Tong, Zhou
    Liu, Lu-Lu
    Zheng, Yi
    Jiang, Wei-Qin
    Zhao, Peng
    Fang, Wei-Jia
    Zhang, Hang-Yu
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2019, 7 (11) : 1253 - 1261
  • [5] Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?
    Jensen, Agnete Witness Praest
    Simoes, Ana Micaela Carnaz
    Straten, Per Thor
    Olofsson, Gitte Holmen
    [J]. CANCERS, 2021, 13 (03) : 1 - 16
  • [6] Interleukin-21 in cancer immunotherapy Friend or foe?
    Stolfi, Carmine
    Pallone, Francesco
    Macdonald, Thomas T.
    Monteleone, Giovanni
    [J]. ONCOIMMUNOLOGY, 2012, 1 (03) : 351 - 354
  • [7] Homeostatic proliferation of NK cells: friend or foe in cellular immunotherapy?
    Marek, Natalia
    Trzonkowski, Piotr
    [J]. IMMUNOTHERAPY, 2011, 3 (06) : 727 - 729
  • [8] Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer
    Song, Jingjing
    Wu, Lihui
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
  • [9] Friend or foe?
    Lawton, Graham
    [J]. NEW SCIENTIST, 2011, 212 (2841) : 46 - 49
  • [10] Friend not foe
    Ogden, Lesley Evans
    [J]. NEW SCIENTIST, 2018, 237 (3164) : 24 - 25